Krebs Biochemicals & Industries Limited Stock NSE India S.E.

Equities

KREBSBIO

INE268B01013

Pharmaceuticals

Market Closed - NSE India S.E. 07:43:54 2024-06-25 EDT 5-day change 1st Jan Change
70.69 INR +0.26% Intraday chart for Krebs Biochemicals & Industries Limited -0.56% -9.78%

Financials

Sales 2022 587M 7.04M 9.61M Sales 2023 521M 6.25M 8.54M Capitalization 1.22B 14.58M 19.91M
Net income 2022 -445M -5.33M -7.29M Net income 2023 -247M -2.96M -4.04M EV / Sales 2022 7.71 x
Net Debt 2022 1.43B 17.14M 23.41M Net Debt 2023 1.83B 21.97M 30.01M EV / Sales 2023 5.85 x
P/E ratio 2022
-6.94 x
P/E ratio 2023
-4.92 x
Employees 210
Yield 2022 *
-
Yield 2023
-
Free-Float 22.45%
More Fundamentals * Assessed data
Dynamic Chart
Krebs Biochemicals & Industries Limited Appoints Rakesh Kalbate as Company Secretary/Compliance Officer CI
Krebs Biochemicals & Industries Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
Krebs Biochemicals & Industries Limited Announces Resignation of Keyur Doshi as Company Secretary, Compliance Officer CI
Krebs Biochemicals & Industries Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Krebs Biochemicals & Industries Limited Appoints Keyur Doshi as Company Secretary, Compliance Officer CI
Andhra Pradesh Pollution Control Board Orders Production Halt at Krebs Biochemicals Plant MT
Krebs Biochemicals & Industries Limited Announces Resignation of Rohit Taparia as Company Secretary and Compliance Officer CI
Krebs Biochemicals & Industries Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Krebs Biochemicals & Industries Limited Approves Resignation of Mr. Pabitrakumar Kalipada Bhattacharya as Managing Director CI
Krebs Biochemicals Limited Announces Executive Changes, Effective 10 August 2023 CI
Krebs Biochemicals Trims Net Loss in Fiscal Q4 MT
Krebs Biochemicals & Industries Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
Krebs Biochemicals Names New CFO MT
Krebs Biochemicals & Industries Limited Approves Appointment of Rohit Taparia as Company Secretary and Compliance Officer CI
Krebs Biochemicals & Industries Limited Approves CFO Changes CI
More news
1 day+0.26%
1 week-0.56%
Current month+14.02%
1 month+4.73%
3 months+6.06%
6 months-12.40%
Current year-9.78%
More quotes
1 week
69.53
Extreme 69.53
75.00
1 month
61.00
Extreme 61
80.20
Current year
60.35
Extreme 60.35
83.00
1 year
60.35
Extreme 60.35
93.95
3 years
50.65
Extreme 50.65
227.90
5 years
50.65
Extreme 50.65
227.90
10 years
50.65
Extreme 50.65
227.90
More quotes
Managers TitleAgeSince
Chief Executive Officer - 21-11-08
Founder 74 91-12-01
Director of Finance/CFO - 23-02-02
Members of the board TitleAgeSince
Director/Board Member 67 00-09-25
Founder 74 91-12-01
Director/Board Member 45 01-12-31
More insiders
Date Price Change Volume
24-06-25 70.69 +0.26% 25,840
24-06-24 70.51 -1.14% 16,785
24-06-21 71.32 -2.27% 12,993
24-06-20 72.98 +1.26% 33,991
24-06-19 72.07 +1.38% 8,828

Delayed Quote NSE India S.E., June 25, 2024 at 07:43 am

More quotes
Krebs Biochemicals & Industries Ltd is an India-based company, which is engaged in the business of manufacture of active pharmaceutical ingredients. The Company manufactures bulk active pharmaceutical ingredients, pharmaceutical intermediates, fine chemicals, nutraceuticals utilizing two revenue streams: contract manufacturing for large pharmaceutical and multinational companies, and development of its products for sale in global markets. Its products include Androstenedione, Lovastatin, and Simvastatin. The Company’s pilot or research and development stages products are Amlodipine, Cetirizine, Orlistat, Serratiopepetidase, Telmisartan, and Phenylephrine. The Company has two manufacturing facilities one at Regadichelaka, Nellore District and another one at Kothapalli Village, Kasimkota Mandal, Visakhapatnam District, Andhra Pradesh, India.
More about the company